MedTrace Logo

Efficacy Study of AGSPT201 Tablet to Treat Gastroesophageal Reflux Disease

NCT01400945 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2011-09-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate treatment in Gastroesophageal Reflux Disease (GERD) patients (aged 18\~75) with endoscopically proven GERD treated with AGSPT201 Tablet.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

AGSPT201 Tab contains S-pantoprazole

comparison of Pantoloc Tab 40mg

Sponsors & Collaborators

  • Ahn-Gook Pharmaceuticals Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • MyoungKyu Choi, M.D · The Catholic University of Korea-St. Mary's Hospital

  • YoungTae Park, M.D. · Korea University Medical Center-Guro

  • PoongRyul Lee, M.D · Samsung Medical Center

  • SangKyun Kim, M.D · Seoul National University Hospital

  • HoonYong Jeong, M.D · Asan Medical Center

  • SangYoung Seol, M.D · Inje University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-08-31
Completion
2011-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01400945 on ClinicalTrials.gov